or Try an Advanced Search...

    Technical Analysis for ENLV - Enlivex Therapeutics Ltd.

    Grade Last Price % Change Price Change
    F 0.93 -5.22% -0.05
    ENLV closed down 5.24 percent on Wednesday, November 20, 2024, on 2.39 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ENLV trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -5.22%
    Expansion Breakdown Bearish Swing Setup -5.22%
    Reversal New Lows Setup Bearish Swing Setup -5.22%
    Lower Bollinger Band Walk Weakness -5.22%
    New 52 Week Low Weakness -5.22%
    Outside Day Range Expansion -5.22%
    Wide Bands Range Expansion -5.22%
    Gapped Up Strength -5.22%
    Down 3 Days in a Row Weakness -5.22%
    Down 4 Days in a Row Weakness -5.22%
    Older End-of-Day Signals for ENLV ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown 43 minutes ago
    Down 5% 43 minutes ago
    Down 3% 43 minutes ago
    Fell Below Lower Bollinger Band 43 minutes ago
    Reversal New Lows Entry 43 minutes ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ENLV Chart by TradingView
    Basic chart:

    Profile

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Immunology Solid Tumors Immune System Immunotherapy Cancer Treatment Tumor Virotherapy Coronavirus Cytokine Inflammatory Conditions

    Is ENLV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
    Oct 31 Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
    Oct 30 Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
    Sep 24 Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
    Aug 30 GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Jul 23 Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
    Jul 19 Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Jun 24 Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
    Jun 20 Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
    Jun 17 Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
    See more ENLV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.59
    52 Week Low 0.93
    Average Volume 162,353
    200-Day Moving Average 1.88
    50-Day Moving Average 1.43
    20-Day Moving Average 1.26
    10-Day Moving Average 1.13
    Average True Range 0.11
    RSI (14) 18.70
    ADX 35.31
    +DI 5.84
    -DI 26.78
    Chandelier Exit (Long, 3 ATRs) 1.31
    Chandelier Exit (Short, 3 ATRs) 1.27
    Upper Bollinger Bands 1.57
    Lower Bollinger Band 0.94
    Percent B (%b) 0.05
    BandWidth 49.57
    MACD Line -0.12
    MACD Signal Line -0.09
    MACD Histogram -0.0274
    Fundamentals Value
    Market Cap 18.15 Million
    Num Shares 18.6 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -0.66
    Price-to-Sales 0.00
    Price-to-Book 1.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.25
    Resistance 3 (R3) 1.26 1.19 1.20
    Resistance 2 (R2) 1.19 1.12 1.18 1.19
    Resistance 1 (R1) 1.08 1.07 1.04 1.07 1.17
    Pivot Point 1.01 1.01 0.99 1.00 1.01
    Support 1 (S1) 0.90 0.94 0.86 0.89 0.78
    Support 2 (S2) 0.83 0.89 0.82 0.77
    Support 3 (S3) 0.72 0.83 0.75
    Support 4 (S4) 0.71